Bank of America just raised its EUR/USD forecast
NEW YORK - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) reported first quarter earnings that beat expectations, but revenue fell short of analyst estimates on Friday.
The company’s shares were down -3.10% in premaket trading following the release.
The generic drug maker posted adjusted earnings per share of $0.21 for Q1 2025, exceeding the consensus estimate of $0.15. However, revenue of $695 million missed Wall Street’s forecast of $726.49 million.
Amneal’s Q1 revenue grew 5% year-over-year, driven by a 6% increase in its Affordable Medicines segment and 3% growth in Specialty products. The company cited strong performance from its complex product portfolio and new product launches.
"Amneal delivered another strong quarter to start 2025, with broad-based growth across all three segments driven by our team’s outstanding execution," said Co-CEOs Chirag and Chintu Patel in a statement.
Despite the revenue miss, Amneal reaffirmed its full-year 2025 guidance. The company expects adjusted EPS of $0.65-$0.70 on revenue of $3.0-$3.1 billion.
The company will host a conference call later today to discuss the results in more detail.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.